Search research articles
Contact Us
Filters
Showing results (31-40 of 84) with videos related to
Page
of 9
Sort By:
Oncology
|
December 6, 2003
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer
Birgit Schüll, Gabriela V Kornek, Katharina Schmid, et al.
The Oncologist
|
November 16, 2020
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, et al.
Therapeutic Advances in Medical Oncology
|
January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
Journal of Gastrointestinal Oncology
|
April 2, 2016
Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
Werner Scheithauer, Gabriela Kornek, Gerald Prager, et al.
Therapeutic Advances in Gastroenterology
|
October 4, 2019
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Werner Scheithauer, Paul Martin Putora, Birgit Grünberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor
Gabriela V Kornek, Karin Haider, Werner Kwasny, et al.
European Journal of Clinical Investigation
|
February 13, 2013
Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features
Johannes Thaler, Cihan Ay, Nigel Mackman, et al.
Cancer Science
|
May 23, 2014
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
Gerald W Prager, Kira H Braemswig, Alexandra Martel, et al.
Cancer Investigation
|
February 21, 2002
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Stefan Brugger, et al.
Page
of 9
Search research articles
Search
Showing results (31-40 of 84) with videos related to
Sort By:
Page
of 9
Oncology
|
December 6, 2003
Effective combination chemotherapy with bimonthly docetaxel and cisplatin with or without hematopoietic growth factor support in patients with advanced gastroesophageal cancer
Birgit Schüll, Gabriela V Kornek, Katharina Schmid, et al.
The Oncologist
|
November 16, 2020
Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer
Alberto Sobrero, Heinz-Josef Lenz, Cathy Eng, et al.
Therapeutic Advances in Medical Oncology
|
January 15, 2019
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Piera Gargiulo, Daniel Dietrich, Richard Herrmann, et al.
Journal of Gastrointestinal Oncology
|
April 2, 2016
Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma
Werner Scheithauer, Gabriela Kornek, Gerald Prager, et al.
Therapeutic Advances in Gastroenterology
|
October 4, 2019
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine
Werner Scheithauer, Paul Martin Putora, Birgit Grünberger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2003
Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Markus Raderer, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 15, 2002
Treatment of advanced breast cancer with docetaxel and gemcitabine with and without human granulocyte colony-stimulating factor
Gabriela V Kornek, Karin Haider, Werner Kwasny, et al.
European Journal of Clinical Investigation
|
February 13, 2013
Microparticle-associated tissue factor activity in patients with pancreatic cancer: correlation with clinicopathological features
Johannes Thaler, Cihan Ay, Nigel Mackman, et al.
Cancer Science
|
May 23, 2014
Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer
Gerald W Prager, Kira H Braemswig, Alexandra Martel, et al.
Cancer Investigation
|
February 21, 2002
Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer
Werner Scheithauer, Gabriela V Kornek, Stefan Brugger, et al.
Page
of 9